Photopharmacology

Lack of probe selectivity is a recurrent problem in pharmacological treatments and is caused by the inability to control the activity of the probe in time and space. We are addressing this issue by incorporating photo-responsive groups (photoswitches and photolabile protecting groups) into the molecular structure of kinase inhibitors. These inhibitors allow for the use of light to externally control activity, which can be delivered with very high spatiotemporal precision.

Collaborators include: Andréasson, König, Lundbäck and CBCS.

A Fluorescent LCK Inhibitor that Exhibits Diagnostic Changes in Emission Upon Binding the Kinase Enzyme, Cassandra Lee Fleming, Patrick A Sandoz, Tord Inghardt, Björn Önfelt, Morten Grøtli, Joakim Andreasson. Angew. Chem. Int. Ed.,  2019, 58, 15000 –15004.

Synthesis and Photophysical Characterization of Azoheteroarenes,  Yongjin Xu, Chunxia Gao, Joakim Andréasson, Morten Grøtli. Org. Lett. 2018, 20, 4875–4879.